The model uses patient-generated data to triage surgical oncology patients with the goal of improving post-surgical outcomes. Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions. Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data. The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response. Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment. It is important to monitor patients who have elevated CMV levels to detect infection and progression early. Results from this meta-review suggest that more prophylactic strategies are needed in the fight against GVHD. Intensive salvage therapy had a 54% complete remission rate whereas non-intensive salvage therapy was lower at 18%. Milagros Elia, MA, APRN, ANP-BC, discusses the tragic fires in Maui and the massive impact these events have on cancer care. The study used only single-agent tacrolimus for GVHD prophylaxis. Non-relapse mortality was low, and there was good GVHD control with the prophylaxis. Results were further improved when Orca-T was given in combination with a regimen of busulfan, fludarabine, and thiotepa. Limited diagnostic resources, such as EPO level tests, can result in late or misdiagnosis and increased health care costs. The average cost of hospitalization for a TE was $4000-9000 higher than for generally medically ill patients. Investigators noted improved spleen size and blood parameters in addition to improvement in PV symptoms. Rusfertide improved response maintenance and reduced the need for therapeutic phlebotomy. The trial cohort achieved a staggering 100% overall response rate after 7 days of treatment. The improvements occurred after haploidentical donor-matched transplant with PTCy and cord blood transplant. Findings from this pilot study suggest that EVs may be a promising avenue for developing ocular GvHD therapies. Differences in microRNA expression could help identify individuals at risk of developing GVHD.